Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial
- 1 June 1999
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 137 (6), 1062-1069
- https://doi.org/10.1016/s0002-8703(99)70363-7
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or FlutterJournal of the American College of Cardiology, 1997
- Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response studyJournal of the American College of Cardiology, 1996
- Intravenous propafenone in paroxysmal atrial fibrillation: A randomized, placebo‐controlled, double‐blind, multicenter clinical trialClinical Cardiology, 1996
- Management of Patients With Atrial FibrillationCirculation, 1996
- Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidineJournal of the American College of Cardiology, 1995
- Dofetilide, A Novel Class III Antiarrhythmic AgentJournal of Cardiovascular Pharmacology, 1992
- Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertensionThe American Journal of Cardiology, 1992
- Management of Atrial FibrillationNew England Journal of Medicine, 1992
- Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutterThe American Journal of Cardiology, 1992
- Conversion of supraventricular arrhythmias to sinus rhythm using flecainideEuropean Heart Journal, 1985